Navigation Links
Sanofi-aventis Announces Second Quarter 2009 Results
Date:7/29/2009

in the Other Countries region (up 31.8% at euro 85 million). First-half net sales of the product were up 6.9% at euro 1,542 million.

No biosimilar of Lovenox((R)) has been approved in the United States to date.

Taxotere((R)) achieved second-quarter growth of 10.7% to euro 584 million, driven by its use in adjuvant breast cancer treatment and in prostate cancer. Growth was good across all three geographic regions, at 10.7% in Europe (to euro 239 million), 9.6% in the United States (to euro 228 million) and 12.7% in the Other Countries region (to euro 117 million). In Japan, the product continued its advance with net sales up 13.4% at euro 34 million, boosted in particular by the prostate cancer indication approved in the second half of 2008.

In June 2009, the Committee for Medicinal Products for Human Use (CHMP) of the EMEA issued a positive opinion on Roche's Avastin((R)) in combination with Taxotere((R)) as a first line treatment for women with metastatic breast cancer, based on the results of the AVADO study. First-half net sales of Taxotere((R)) were up 9.5% at euro 1,118 million.

Eloxatin((R)), the leading cytotoxic agent in the colorectal cancer market as an adjuvant and as a first-line treatment in the metastatic phase, achieved second-quarter growth of 10.0% in the United States to euro 282 million. Total net sales of the product reflect ongoing competition from generics in Europe, and were down 4.3% at euro 353 million. First-half net sales of Eloxatin((R)) were down 5.7% at euro 697 million. In June 2009, the U.S. District Court for the District of New Jersey ruled against sanofi-aventis by granting summary judgment motions brought by certain generics companies in the U.S. Eloxatin((R)) patent litigation. Sanofi-aventis has appealed this decision, and the Appellate Court issued an order temporarily staying the district court's judgment. As of th
'/>"/>

SOURCE sanofi-aventis
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27

Related biology technology :

1. Sanofi-aventis Announces Settlement of Average Wholesale Price Civil Suits With the U.S. Department of Justice Relating to Anzemet(R)
2. Shareholder Class Action Filed Against Sanofi-Aventis by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
3. Sanofi-aventis SoloSTAR(R) Insulin Pen for Lantus and Apidra Receives the Prestigious GOOD DESIGN Award
4. ThalesNano Inc. and sanofi-aventis R&D Collaborate on Continuous Process Chemistry in Order to Dramatically Reduce Drug Realization Time
5. RainDance Technologies Signs a Collaboration Agreement with sanofi-aventis and Louis Pasteur University to Launch dScreen Consortium within ALSACE BIOVALLEY cluster
6. AEterna Zentaris and Sanofi-Aventis Sign a Development, Commercialization and Licensing Agreement for Cetrorelix in Benign Prostatic Hyperplasia
7. BioWa Announces License of POTELLIGENT(R) Technology to sanofi-aventis
8. Sanofi-aventis U.S. to Acquire Oral Chronic Lymphocytic Leukemia Treatment
9. Sanofi-aventis U.S. Announces Settlement of Medicaid Best Price Investigation
10. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
11. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/18/2015)... Aurigene and its partner ... presenting data at the poster sessions from two ... Annual Meeting (April 18-22 in Philadelphia, ... http://photos.prnewswire.com/prnh/20130418/608115 ) , Aurigene will present ... molecule inhibitors program, which is currently in preclinical ...
(Date:4/17/2015)... 2015 Reed Technology and Information ... data management, preparation, and submission to the U.S. Food ... a new Lot Distribution Report (LDR) service for manufacturers ... compliant with the FDA’s new rule on electronic submission ... monitor the volume and timing of particular biologics introduced ...
(Date:4/17/2015)... - SQI Diagnostics Inc. (TSX-V: SQD; OTCQX: SQIDF), a ... commercializes proprietary technologies and products for advanced microarray ... approval from the TSX Venture Exchange to extend ... warrants ("the Warrants") of the Company, which were ... private placement financing. Each Warrant entitles ...
(Date:4/17/2015)... , April 17, 2015  US-Australian drug discovery company, ... Memorandum of Understanding with the Feinstein Institute for ... York to collaborate with the objective ... The collaboration brings together the drug discovery ... expertise of the Feinstein Institute in neurosciences and ...
Breaking Biology Technology:Aurigene to Present its NAMPT and IRAK-4 Inhibitors Programs at AACR 2015 2Reed Tech Announces FDA Lot Distribution Report (LDR) Service for Manufacturers of Biologic Products 2Reed Tech Announces FDA Lot Distribution Report (LDR) Service for Manufacturers of Biologic Products 3SQI Diagnostics to Extend Warrant Expiry 2SQI Diagnostics to Extend Warrant Expiry 3Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 2Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 3Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 4Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 5Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 6
... Been Filed With the FDA for the Fourth Genmab ... Under the Company,s Collaboration with Roche., COPENHAGEN, December ... Investigational New Drug application (IND) for a,Genmab antibody developed ... the FDA by Roche. Genentech and Roche are collaborating ...
... Dec. 11 The Tauri Group LLC is ... provide Systems Engineering and,Technical Assistance (SETA) support for ... Health Affairs Early Detection Division Chemical,and Biological Early ... $38 million and the period of performance is ...
... 11 PPD, Inc. (Nasdaq:,PPDI) will release its fiscal ... the market closes. The release will be available on,the ... PR Newswire., On Wednesday, January 9, 2008, at ... and audio webcast to discuss its financial guidance for,fiscal ...
Cached Biology Technology:Fourth Genmab Antibody Developed Under Roche Collaboration to Enter Clinic 2Fourth Genmab Antibody Developed Under Roche Collaboration to Enter Clinic 3The Tauri Group LLC Awarded U.S. Department of Homeland Security Chemical and Biological Early Detection Systems Program Office Support Contract 2PPD Announces 2008 Financial Guidance Webcast and Conference Call 2
(Date:4/2/2015)... , April 2, 2015 According ... 2015 attributed to somewhat higher than 125 MSEK. This ... year-end report 2014 that revenues for Q1 2015 would ... company reported for Q4 2014. The operating result for ... negative. The complete interim report will as previously communicated ...
(Date:4/1/2015)... , April 1, 2015   Medisafe ™, the ... users across iOS and Android ... integrating biofeedback into the platform to allow patients to ... For the first time, patients will be able to ... dose impacts important biometrics, such as glucose levels and ...
(Date:3/30/2015)... Mar. 26, 2015 Research and Markets ... "Global Gesture Recognition Market in Automotive Sector 2014-2018" ... forecast the Global Gesture Recognition market in Automotive Sector ... period 2013-2018. Gesture recognition is the ability ... gestures of an individual. Gesture recognition technology can be ...
Breaking Biology News(10 mins):Fingerprint Cards Revises Revenues for Q1 2015 2Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2
... unique aroma signature of the durian revered as the ... the world,s foulest smelling food has uncovered several new ... ACS, Journal of Agricultural and Food Chemistry . ... food shops in the United States and elsewhere, has a ...
... in a Duke University-led study contained potentially toxic or untested chemical ... Among the chemicals detected was "Tris," a chlorinated flame ... studies. "Tris was phased out from use in ... it still showed up in 41 percent of the couch foam ...
... Toronto, ON (27 November, 2012) -- A new method of ... The discovery, which transforms aged stem cells into cells that ... to grow cardiac patches for damaged or diseased hearts from ... avoiding the threat of rejection. Stem cell therapies ...
Cached Biology News:Potentially toxic flame retardants found in many US couches 2'Fountain of youth' technique rejuvenates aging stem cells 2
Human FADD Affinity Purified Polyclonal Ab...
(3-[125I]iodotyrosyl26)Galanin (porcine), 925 kBq, 25 uCi. Category: IODINE LIGANDS....
... high-performance triple quadrupole 1200L sets the ... cost-conscious environment - incorporating the latest ... all liquid chromatography analytical needs. ... and the Transmission Quadrupole Analyzer provide ...
Immunogen: Synthetic Peptide: V(22) N G H E F E I E G E G E G R(36) Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products: